Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1995 1
1997 1
1998 1
1999 2
2000 2
2001 4
2002 6
2003 4
2004 3
2005 1
2006 7
2007 4
2008 7
2009 7
2010 8
2011 4
2012 13
2013 11
2014 8
2015 7
2016 6
2017 10
2018 12
2019 8
2020 3
2021 4
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Results by year

Filters applied: . Clear all
Page 1
A homogeneous high-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides.
Zacharias N, Podust VN, Kajihara KK, Leipold D, Del Rosario G, Thayer D, Dong E, Paluch M, Fischer D, Zheng K, Lei C, He J, Ng C, Su D, Liu L, Masih S, Sawyer W, Tinianow J, Marik J, Yip V, Li G, Chuh J, Morisaki JH, Park S, Zheng B, Hernandez-Barry H, Loyet KM, Xu M, Kozak KR, Phillips GL, Shen BQ, Wu C, Xu K, Yu SF, Kamath A, Rowntree RK, Reilly D, Pillow T, Polson A, Schellenberger V, Hazenbos WLW, Sadowsky J. Zacharias N, et al. Among authors: kozak kr. Chem Sci. 2022 Jan 28;13(11):3147-3160. doi: 10.1039/d1sc05243h. eCollection 2022 Mar 16. Chem Sci. 2022. PMID: 35414872 Free PMC article.
Calicheamicin Antibody-Drug Conjugates with Improved Properties.
Vollmar BS, Frantz C, Schutten MM, Zhong F, Del Rosario G, Go MAT, Yu SF, Leipold DD, Kamath AV, Ng C, Xu K, Dela Cruz-Chuh J, Kozak KR, Chen J, Xu Z, Wai J, Adhikari P, Erickson HK, Dragovich PS, Polson AG, Pillow TH. Vollmar BS, et al. Among authors: kozak kr. Mol Cancer Ther. 2021 Jun;20(6):1112-1120. doi: 10.1158/1535-7163.MCT-20-0035. Epub 2021 Mar 15. Mol Cancer Ther. 2021. PMID: 33722856
Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy.
Dragovich PS, Pillow TH, Blake RA, Sadowsky JD, Adaligil E, Adhikari P, Chen J, Corr N, Dela Cruz-Chuh J, Del Rosario G, Fullerton A, Hartman SJ, Jiang F, Kaufman S, Kleinheinz T, Kozak KR, Liu L, Lu Y, Mulvihill MM, Murray JM, O'Donohue A, Rowntree RK, Sawyer WS, Staben LR, Wai J, Wang J, Wei B, Wei W, Xu Z, Yao H, Yu SF, Zhang D, Zhang H, Zhang S, Zhao Y, Zhou H, Zhu X. Dragovich PS, et al. Among authors: kozak kr. J Med Chem. 2021 Mar 11;64(5):2576-2607. doi: 10.1021/acs.jmedchem.0c01846. Epub 2021 Feb 17. J Med Chem. 2021. PMID: 33596073
Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties.
Dragovich PS, Pillow TH, Blake RA, Sadowsky JD, Adaligil E, Adhikari P, Bhakta S, Blaquiere N, Chen J, Dela Cruz-Chuh J, Gascoigne KE, Hartman SJ, He M, Kaufman S, Kleinheinz T, Kozak KR, Liu L, Liu L, Liu Q, Lu Y, Meng F, Mulvihill MM, O'Donohue A, Rowntree RK, Staben LR, Staben ST, Wai J, Wang J, Wei B, Wilson C, Xin J, Xu Z, Yao H, Zhang D, Zhang H, Zhou H, Zhu X. Dragovich PS, et al. Among authors: kozak kr. J Med Chem. 2021 Mar 11;64(5):2534-2575. doi: 10.1021/acs.jmedchem.0c01845. Epub 2021 Feb 17. J Med Chem. 2021. PMID: 33596065
Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response.
Dela Cruz Chuh J, Go M, Chen Y, Guo J, Rafidi H, Mandikian D, Sun Y, Lin Z, Schneider K, Zhang P, Vij R, Sharpnack D, Chan P, de la Cruz C, Sadowsky J, Seshasayee D, Koerber JT, Pillow TH, Phillips GD, Rowntree RK, Boswell CA, Kozak KR, Polson AG, Polakis P, Yu SF, Dragovich PS, Agard NJ. Dela Cruz Chuh J, et al. Among authors: kozak kr. MAbs. 2021 Jan-Dec;13(1):1862452. doi: 10.1080/19420862.2020.1862452. MAbs. 2021. PMID: 33382956 Free PMC article.
Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody-Drug Conjugates.
Staben LR, Chen J, Cruz-Chuh JD, Del Rosario G, Go MA, Guo J, Khojasteh SC, Kozak KR, Li G, Ng C, Lewis Phillips GD, Pillow TH, Rowntree RK, Wai J, Wei B, Xu K, Xu Z, Yu SF, Zhang D, Dragovich PS. Staben LR, et al. Among authors: kozak kr. J Med Chem. 2020 Sep 10;63(17):9603-9622. doi: 10.1021/acs.jmedchem.0c00691. Epub 2020 Aug 18. J Med Chem. 2020. PMID: 32787101
Correction: An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast Cancer.
Bhakta S, Crocker LM, Chen Y, Hazen M, Schutten MM, Li D, Kuijl C, Ohri R, Zhong F, Poon KA, Go MAT, Cheng E, Piskol R, Firestein R, Fourie-O'Donohue A, Kozak KR, Raab H, Hongo JA, Sampath D, Dennis MS, Scheller RH, Polakis P, Junutula JR. Bhakta S, et al. Among authors: kozak kr. Mol Cancer Ther. 2019 Nov;18(11):2182. doi: 10.1158/1535-7163.MCT-19-0749. Mol Cancer Ther. 2019. PMID: 31676543 No abstract available.
132 results